Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways.
about
Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function.Obesity alters gene expression for GH/IGF-I axis in mouse mammary fat pads: differential role of cortistatin and somatostatin.Simvastatin downregulates expression of TGF-βRII and inhibits proliferation of A549 cells via ERK.Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
P2860
Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Somatostatin inhibits hepatic ...... K and PI3K signaling pathways.
@en
Somatostatin inhibits hepatic ...... K and PI3K signaling pathways.
@nl
type
label
Somatostatin inhibits hepatic ...... K and PI3K signaling pathways.
@en
Somatostatin inhibits hepatic ...... K and PI3K signaling pathways.
@nl
prefLabel
Somatostatin inhibits hepatic ...... K and PI3K signaling pathways.
@en
Somatostatin inhibits hepatic ...... K and PI3K signaling pathways.
@nl
P2860
P1476
Somatostatin inhibits hepatic ...... K and PI3K signaling pathways.
@en
P2093
Alison L Hagemeister
Mark A Sheridan
P2860
P304
P356
10.1152/AJPREGU.00099.2008
P577
2008-05-21T00:00:00Z